| HOME | HELP | E-MAIL ALERTS | SEARCH |
|
| ||||||||||||||||||||||||||||||||||||||||||||||
These guidelines are designed to provide a format allowing for the protection of child subjects in drug research. Research involving children carries with it additional responsibilities for the investigator, IRB, and sponsor. The additional responsibilities should not be reasons for the pharmaceutical company, IRB, or the investigator to exclude children from drug research and its potential benefits. It is hoped that these guidelines foster an increase in the number of drug investigations carried out in children, thereby improving their health care.
The AAP believes it is unethical to deny children appropriate access to existing and new therapeutic agents. It is the combined responsibility of the pediatric community, pharmaceutical industry, and regulatory agencies to conduct the necessary studies; it is the responsibility of the general public to support the necessary research in order to assure that all children have access to important medications and receive optimal drug therapy.
Statement of reaffirmation:
The following policy statement has been revised:
This article has been cited by other articles:
 |
|
 |
|
  P. B. Smith, D. K. Benjamin Jr, M. D. Murphy, R. Johann-Liang, S. Iyasu, B. Gould, R. M. Califf, J. S. Li, and W. Rodriguez Safety Monitoring of Drugs Receiving Pediatric Marketing Exclusivity Pediatrics, September 1, 2008; 122(3): e628 - e633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. B. Smith, J. S. Li, M. D. Murphy, R. M. Califf, and D. K. Benjamin Jr Safety of Placebo Controls in Pediatric Hypertension Trials Hypertension, April 1, 2008; 51(4): 829 - 833. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Berg Ethical Challenges in Cancer Research in Children Oncologist, November 1, 2007; 12(11): 1336 - 1343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Glasser, M. Salas, and E. Delzell Importance and Challenges of Studying Marketed Drugs: What Is a Phase IV Study? Common Clinical Research Designs, Registries, and Self-Reporting Systems J. Clin. Pharmacol., September 1, 2007; 47(9): 1074 - 1086. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Shah, M. Hall, D. M. Goodman, P. Feuer, V. Sharma, C. Fargason Jr, D. Hyman, K. Jenkins, M. L. White, F. H. Levy, et al. Off-label Drug Use in Hospitalized Children Arch Pediatr Adolesc Med, March 1, 2007; 161(3): 282 - 290. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Bagley, W. W. Reynolds, and R. M. Nelson Is a "Wage-Payment" Model for Research Participation Appropriate for Children? Pediatrics, January 1, 2007; 119(1): 46 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Stevens-Simon Assent in Pediatric Research Pediatrics, October 1, 2006; 118(4): 1800 - 1801. [Full Text] [PDF]
|
|
|
|
|
|
A. A. Kon Assent in Pediatric Research Pediatrics, May 1, 2006; 117(5): 1806 - 1810. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Y. Yoon, M. M. Davis, H. El-Essawi, and M. D. Cabana FDA Labeling Status of Pediatric Medications Clinical Pediatrics, January 1, 2006; 45(1): 75 - 77. [PDF]
|
|
|
|
 |
|
 B. A. Brody, L. B. McCullough, and R. R. Sharp Consensus and Controversy in Clinical Research Ethics JAMA, September 21, 2005; 294(11): 1411 - 1414. [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Robertson Cancer and Fertility: Ethical and Legal Challenges J Natl Cancer Inst Monographs, March 1, 2005; 2005(34): 104 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Whittle, S. Shah, B. Wilfond, G. Gensler, and D. Wendler Institutional Review Board Practices Regarding Assent in Pediatric Research Pediatrics, June 1, 2004; 113(6): 1747 - 1752. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. H. Sharav Conflicts of Interest in Biomedical Research Harm Children With and Without Disabilities Journal of Disability Policy Studies, January 1, 2004; 15(1): 50 - 59. [Abstract] [PDF]
|
|
|
|
|
|
J. T. Flynn Ethics of Placebo Use in Pediatric Clinical Trials: The Case of Antihypertensive Drug Studies Hypertension, November 1, 2003; 42(5): 865 - 869. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T Holdsworth Pediatric Drug Research -- The Road Less Traveled Ann. Pharmacother., April 1, 2003; 37(4): 586 - 591. [Full Text] [PDF]
|
|
|
|
|
|
S. A. Gillman, M. Blatter, J. J. Condemi, M. Collins, A. O. Olufade, N. K. Leidy, D. Chapman, and B. Kramer The Health-Related Quality of Life Effects of Once-Daily Cetirizine HCl Syrup in Children with Seasonal Allergic Rhinitis Clinical Pediatrics, November 1, 2002; 41(9): 687 - 696. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Steinbrook Testing Medications in Children N. Engl. J. Med., October 31, 2002; 347(18): 1462 - 1470. [Full Text] [PDF]
|
|
|
|
|
|
K. L. Weise, M. L. Smith, K. J. Maschke, and H. L. Copeland National Practices Regarding Payment to Research Subjects for Participating in Pediatric Research Pediatrics, September 1, 2002; 110(3): 577 - 582. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. O. Erb, S. R. Schulman, and J. Sugarman Permission and Assent for Clinical Research in Pediatric Anesthesia Anesth. Analg., May 1, 2002; 94(5): 1155 - 1160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Botkin, E. Clayton, R. Nelson, B. Wilfond, M. A. Munger, F. G. Miller, A. F. Shorr, L. Friedman Ross, S. J. Fowler, B. J. Lipworth, et al. Salmeterol and Inhaled Corticosteroids in Patients With Persistent Asthma JAMA, December 26, 2001; 286(24): 3075 - 3078. [Full Text] [PDF]
|
|
|
|
|
|
C. Berlin Are We Losing Good Drugs? Clinical Pediatrics, June 1, 2001; 40(6): 325 - 326. [PDF]
|
|
|
|
 |
|
 M. Seid, J. W. Varni, and P. S. Kurtin Measuring Quality of Care for Vulnerable Children: Challenges and Conceptualization of a Pediatric Outcome Measure of Quality American Journal of Medical Quality, July 1, 2000; 15(4): 182 - 188. [Abstract] [PDF]
|
|
|
|
|
|
E. J. Emanuel, D. Wendler, and C. Grady What Makes Clinical Research Ethical? JAMA, May 24, 2000; 283(20): 2701 - 2711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Pellock Managing Pediatric Epilepsy Syndromes With New Antiepileptic Drugs Pediatrics, November 1, 1999; 104(5): 1106 - 1116. [Abstract] [Full Text]
|
|
|
|
|
|
J. L. Blumer Off-Label Uses of Drugs in Children Pediatrics, September 1, 1999; 104(3): 598 - 602. [Full Text]
|
|
|
|
|
|
S. N. Cohen The Pediatric Pharmacology Research Unit (PPRU) Network and Its Role in Meeting Pediatric Labeling Needs Pediatrics, September 1, 1999; 104(3): 644 - 645. [Full Text]
|
|
|
|
|
|
Committee on Drugs Alternative Routes of Drug Administration---Advantages and Disadvantages (Subject Review) Pediatrics, July 1, 1997; 100(1): 143 - 152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Rehman, K. M. Sullivan, M. C. Walters, and K. Ohene-Frempong Bone Marrow Transplantation for Sickle Cell Disease N. Engl. J. Med., December 12, 1996; 335(24): 1845 - 1846. [Full Text]
|
|
|
|
 |
|
 A. M. Dellinger Subjected to Science: Human Experimentation in America before the Second World War. Journal of Health Politics Policy and Law, March 1, 1996; 21(1): 159 - 166. [PDF]
|
|
|
|
|
|
A. M. Dellinger Children as Research Subjects: Science, Ethics, and Law. Journal of Health Politics Policy and Law, March 1, 1996; 21(1): 159 - 166. [PDF]
|
|
| HOME | HELP | E-MAIL ALERTS | SEARCH |
